RevOpsis Therapeutics
RevOpsis
Dover, United States · Founded 2022 · $16.5M raised
- Headquarters
- Dover
- Employees
- 1–10
- Founded
- 2022
- Business Model
- B2B
- Website
- revopsis.com
- Total Funding
- $16.5M
- Last Round
- $16.5M SeedAug 2023
- Rounds
- 1
About
RevOpsis Therapeutics is a next-generation biopharmaceutical company developing multispecific antibody therapies using its proprietary Rev-Mod Platform. Its lead asset RO-104 is a trispecific biologic targeting retinal vascular diseases including neovascular age-related macular degeneration. Based in Dover, Delaware with 2-10 employees.
Summary
RevOpsis Therapeutics is a Biotechnology company based in Dover, United States, founded in 2022. It has raised $16.5M in total across 1 round, most recently a $16.5M Seed round in Aug 2023.
Tech & App Stack
3 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Aug 2023
Similar Companies
Leading innovative radiopharmaceutical company in China developing next-generation radiopharmaceu...
Clinical-stage biotechnology company pioneering GPCR drug discovery through its proprietary Nativ...
Clinical-stage ophthalmic gene therapy company developing AAV-based treatments for rare and preva...
Belgian agricultural biotech company developing microbial-based biocontrol and biostimulant produ...
Clinical-stage biotechnology company developing in vivo CRISPR gene editing therapies for severe ...
Biotech company developing novel GPCR-targeting therapeutics using conformation-specific nanobodies.